Sheppard Mullin advised Unicycive Therapeutics in the transaction. Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, executed its $50...
Unicycive Therapeutics’ $50 Million Private Placement
Unicycive Therapeutics’ $130 Million Private Placement
Sheppard Mullin advised Unicycive Therapeutics on the deal. Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney...